Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Contrast Induced Nephropathy Clear all
Terminated Not applicable Interventional

Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury

NCT04877847
View directory record Official record
Conditions
Contrast-induced Nephropathy, Chronic Kidney Diseases
Interventions
Low-frequency therapeutic ultrasound (LOTUS), LOTUS System with Ultrasound Disabled
Device
Lead sponsor
Sonogenix
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Detroit, Michigan • Petoskey, Michigan • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 3, 2026, 3:10 PM EDT
Terminated Phase 1 Interventional

Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure

NCT00575419
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
N-acetylcysteine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 3, 2026, 3:10 PM EDT
Terminated Phase 3 Interventional

Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease

NCT00930436
View directory record Official record
Conditions
Contrast Induced Kidney Injury.
Interventions
sodium bicarbonate
Drug
Lead sponsor
MD Scientific
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Rome, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Sep 3, 2026, 3:10 PM EDT
Withdrawn No phase listed Observational

Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography

NCT03806725
View directory record Official record
Conditions
Acute Kidney Injury, Renal Insufficiency, Chronic, Contrast-induced Nephropathy, Liver Transplantation, Contrast Media
Interventions
Intravenous administration of iodinated contrast medium for coronary CT angiography
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Sep 3, 2026, 3:10 PM EDT
Recruiting Not applicable Interventional

Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.

NCT05147831
View directory record Official record
Conditions
Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI), Contrast-induced Nephropathy Following Coronary Angiogram (CIN)
Interventions
Remote Ischemic Preconditioning
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 3, 2026, 3:10 PM EDT
Not listed Phase 3 Interventional

Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients

NCT01456013
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
RenalGuard Therapy, Standard Therapy
Device · Drug
Lead sponsor
CardioRenal Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 3, 2026, 3:10 PM EDT
Terminated Not applicable Interventional

Remote Ischemic Preconditioning to Prevent Contrast Nephropathy

NCT02674451
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Remote ischemic preconditioning
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 3, 2026, 3:10 PM EDT
Completed No phase listed Observational Results available

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

NCT00744939
View directory record Official record
Conditions
Fibrosis, Kidney Failure, Renal Insufficiency
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 3, 2026, 3:10 PM EDT
Completed No phase listed Observational

The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases

NCT00842868
View directory record Official record
Conditions
Atherosclerosis, Contrast Induced Nephropathy, Renal Impairment
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Sep 3, 2026, 3:10 PM EDT
Not listed Not applicable Interventional

Monitoring Renal Blood Flow With Contrast Enhanced Ultrasound During Coronary Angiogram

NCT01544036
View directory record Official record
Conditions
Contrast Induced Acute Kidney Injury
Interventions
perflutren
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Phase 2 Interventional

Contrast Enhanced Ultrasound for Renal Obstruction

NCT05090800
View directory record Official record
Conditions
Kidney; Obstruction, Renal Obstruction
Interventions
Definity contrast during ultrasound
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Not applicable Interventional

Remote Ischemic Preconditioning for Renal Protection in TAVI

NCT03347032
View directory record Official record
Conditions
Aortic Valve Stenosis, Renal Insufficiency, Contrast-induced Nephropathy
Interventions
Remote ischemic preconditioning, Control
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Phase 2 Interventional

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

NCT05758896
View directory record Official record
Conditions
Contrast Induced Acute Kidney Injury
Interventions
Isuzinaxib (APX-115), Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 3, 2026, 3:10 PM EDT
Recruiting No phase listed Observational

Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury

NCT07197957
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
BayCare Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Clearwater, Florida • New Port Richey, Florida • Safety Harbor, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Not applicable Interventional Results available

Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury

NCT03236441
View directory record Official record
Conditions
Contrast-induced Acute Kidney Injury
Interventions
RIPC, Sham-RIPC
Device
Lead sponsor
Oladipupo Olafiranye, MD, MS
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Not applicable Interventional Results available

AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN

NCT01976299
View directory record Official record
Conditions
Contrast Induced Nephropathy (CIN)
Interventions
AVERT
Device
Lead sponsor
Osprey Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Phase 4 Interventional

Patients With Renal Impairment Undergoing CT

NCT00292487
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Iopamidol 370 mgI/mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 3, 2026, 3:10 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate

NCT00579995
View directory record Official record
Conditions
Nephropathy
Interventions
Oral N-Acetylcysteine, Sodium Bicarbonate
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Phase 4 Interventional Results available

Contrast Nephropathy and Nitrates

NCT01999517
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Intravenous Nitroglycerin, IV Fluids
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Phase 2 Interventional

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

NCT01146925
View directory record Official record
Conditions
Contrast-Induced Acute Kidney Injury
Interventions
CRMD-001-Deferiprone, Placebo
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Indianapolis, Indiana • Detroit, Michigan • Petoskey, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 3, 2026, 3:10 PM EDT
Not listed No phase listed Observational

DyeVert™ System for Contrast Monitoring in At-Risk Patients Undergoing Angiography: A Real-World Registry

NCT03825094
View directory record Official record
Conditions
Patients at Risk for Developing Contrast-induced Nephropathy
Interventions
DyeVert™ Contrast Reduction Systems
Device
Lead sponsor
Osprey Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Hartford, Connecticut • Hialeah, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Sep 3, 2026, 3:10 PM EDT
Recruiting Phase 4 Interventional

Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-Risk Patients With the Use of the Dye-Vert Plus System

NCT04279457
View directory record Official record
Conditions
AKI (Acute Kidney Injury) Due to Trauma
Interventions
DyeVert Plus System, Standardized hydration protocol
Device · Other
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
1,802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 3, 2026, 3:10 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

NCT00793182
View directory record Official record
Conditions
Renal Impairment
Interventions
Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 3, 2026, 3:10 PM EDT
Completed Phase 3 Interventional

Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate

NCT00312117
View directory record Official record
Conditions
Contrast Induced Nephropathy, Kidney Diseases
Interventions
Sodium bicarbonate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 3, 2026, 3:10 PM EDT